• Username (E-mail)
  • Password
Dow 20,761 -0.2%  EStoxx50 3,304 -0.9%  Nikkei 19,284 -0.5%  EUR 1.0568 -0.1% 
Nasdaq 5,826 -0.2%  FTSE100 7,244 -0.4%  Yen 112.1080 -0.5%  Oil 56.0 -0.8% 
S&P500 2,359 -0.2%  DAX 11,804 -1.2%  GBP 1.2462 -0.7%  Gold 1,257 0.6% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

01/11/2017 09:11:51 AM
01/11/2017 09:11:51 AM UTC-0500

Merck KGaA Licenses Four Oncology R&D Programs From Vertex

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.

As part of the agreement, Merck KGaA, Darmstadt, Germany will license two clinical-stage programs targeting DNA damage and repair, along with two additional novel pre-clinical programs.

Vertex will receive an upfront payment of $230 million, in addition to royalties on future net sales. Merck KGaA, Darmstadt, Germany will assume full responsibility for the development and commercialization of all the programs.

The collaboration, and the related $230 million upfront payment, is subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
Vertex Pharmaceuticals Goldman Sachs Group Inc.
Vertex Pharmaceuticals RBC Capital Markets
Vertex Pharmaceuticals Credit Suisse Group
Vertex Pharmaceuticals Goldman Sachs Group Inc.
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Stock Market

News Ticker


  • News on Stocks
  • All News